Steven Katz, MD
Ophthalmology · Columbus, OHNPI 1518906866
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $212,303 of the $256,210 with a category attached, or 82.9%. Amgen accounts for 79.0% of it on its own, with 28 other manufacturers making up the rest. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,116 payments — averaging $229.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$202K
- AbbVie$42K
- Argenx US, Inc.$5K
- Teva Pharmaceuticals USA, Inc.$1K
- AstraZeneca$888
- Pfizer$720
- plus $4K from 23 others
What the payments were for
- Consulting fees$11,7455%
- Speaking & faculty fees$212,30383%
- Travel & lodging$13,1215%
- Food & beverage$18,8187%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 273 | $202,411 |
| AbbVie(2 entities) | 339 | $41,942 |
| Argenx US, Inc. | 46 | $5,142 |
| Teva Pharmaceuticals USA, Inc. | 118 | $1,292 |
| AstraZeneca | 41 | $888 |
| Pfizer | 49 | $720 |
| Supernus Pharmaceuticals, Inc. | 50 | $526 |
| Genentech USA, Inc. | 35 | $504 |
| Mallinckrodt Hospital Products Inc. | 18 | $418 |
| Sun Pharmaceutical Industries Inc. | 25 | $378 |
| Biohaven Pharmaceutical Holding Company Ltd. | 30 | $323 |
| Biohaven Pharmaceuticals, Inc. | 22 | $237 |
| ANI Pharmaceuticals, Inc. | 8 | $177 |
| Lundbeck LLC | 9 | $155 |
| Axsome Therapeutics, Inc. | 8 | $138 |
| Oyster Point Pharma, Inc. | 7 | $134 |
| Johnson & Johnson | 2 | $122 |
| Bausch & Lomb Americas Inc. | 6 | $105 |
| Harrow Eye, LLC | 4 | $101 |
| Alcon | 4 | $100 |
| Impel Pharmaceuticals Inc. | 6 | $95 |
| Novartis | 4 | $69 |
| Merz Pharmaceuticals, LLC | 3 | $56 |
| Kala Pharmaceuticals, Inc. | 2 | $43 |
| Impel Pharmaceuticals LLC | 2 | $42 |
| Springworks Therapeutics, Inc. | 2 | $35 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$256,210 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepezzaTeprotumumab-Trbw | 11 | $669,525 |
| VyvgartEfgartigimod Alfa-Fcab | 14 | $433,117 |
| QuliptaAtogepant | 99 | $145,965 |
| UbrelvyUbrogepant | 63 | $105,539 |
| Nurtec OdtRimegepant Sulfate | 39 | $64,714 |
| RestasisCyclosporine | 72 | $53,729 |
| RocklatanNetarsudil Mesylat/Latanoprost | 73 | $28,011 |
| Restasis MultidoseCyclosporine | 15 | $12,590 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,529 |
| CequaCyclosporine | 19 | $11,801 |
| Cyclosporine | 22 | $8,259 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 11 | $6,768 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 141 | $5,688 |
| Pyridostigmine Bromide | 67 | $3,802 |
| Acetazolamide ErAcetazolamide | 28 | $3,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $202,411 | $669,52511 claims |
| Argenx US, Inc.Vyvgart | $5,142 | $433,11714 claims |
| AbbVieQulipta, Ubrelvy, Restasis, Restasis Multidose | $41,942 | $317,822249 claims |
| PfizerNurtec Odt | $720 | $64,71439 claims |
| Bausch & Lomb Americas Inc.Miebo | $105 | $12,52917 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $378 | $11,80119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- Alice EpitropoulosColumbus$531K
- David LehmannColumbus$58K
- Lisa BorkowskiColumbus$25K
- Thomas MendelColumbus$15K
- Norman BakerColumbus$11K
- Carrie LembachColumbus$11K
- John ChristoforidisColumbus$10K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.